Title:
SMARCA2/4 INHIBITION AS A STRATEGY TO TREAT TUMORS THAT HARBOR ABERRANT BAF ASSEMBLIES
Document Type and Number:
WIPO Patent Application WO/2023/133221
Kind Code:
A3
Abstract:
The present disclosure is concerned with substituted quinazoline-2,4-diamines and compositions for the treatment of disorders associated with altered expression of SMARCA2 and/or SMARCA4 such as, for example, cancer (e.g, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Inventors:
GUPTA YOGESH (US)
MCHARDY STANTON (US)
MCHARDY STANTON (US)
Application Number:
PCT/US2023/010236
Publication Date:
August 17, 2023
Filing Date:
January 05, 2023
Export Citation:
Assignee:
UNIV TEXAS (US)
International Classes:
A61K31/33; A61K31/395; A61K31/40
Other References:
MOHAMED ET AL.: "2,4-Disubstituted quinazolines as amyloid-b aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies", EUROPEAN, JOURNAL OF MEDICINAL CHEMISTRY, vol. 126, 2017, pages 823 - 843, XP029885715, DOI: 10.1016/j.ejmech.2016.12.005
PARK ET AL.: "METABOLISM OF FLUORINE-CONTAINING DRUGS", ANNU. REV. PHARMACOL. TOXICOL., vol. 41, 2001, pages 443 - 70, XP009114978, DOI: 10.1146/annurev.pharmtox.41.1.443
DATABASE PUBCHEM SUBSTANCE ANONYMOUS : "AKOS019371176", XP093085434, retrieved from PUBCHEM
YANG ET AL.: "Discovery and lead identification of quinazoline-based BRD4 inhibitors", BIOORG MED CHEM LETT., vol. 28, no. 21, 2018, pages 3483 - 3488, XP085499074, DOI: 10.1016/j.bmcl.2018.08.039
PARK ET AL.: "METABOLISM OF FLUORINE-CONTAINING DRUGS", ANNU. REV. PHARMACOL. TOXICOL., vol. 41, 2001, pages 443 - 70, XP009114978, DOI: 10.1146/annurev.pharmtox.41.1.443
DATABASE PUBCHEM SUBSTANCE ANONYMOUS : "AKOS019371176", XP093085434, retrieved from PUBCHEM
YANG ET AL.: "Discovery and lead identification of quinazoline-based BRD4 inhibitors", BIOORG MED CHEM LETT., vol. 28, no. 21, 2018, pages 3483 - 3488, XP085499074, DOI: 10.1016/j.bmcl.2018.08.039
Attorney, Agent or Firm:
SHORTELL, D., Brian et al. (US)
Download PDF:
Previous Patent: LUMINAL TISSUE ISOLATION DEVICE AND METHODS FOR USING SAME
Next Patent: SPAN TO SPAN DUCT COUPLER
Next Patent: SPAN TO SPAN DUCT COUPLER